LSTA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
100.0K
70.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
100.0K
70.0K
Operating Expenses
4.0M
-19.2%
4.9M
+55.5%
3.2M
-28.0%
4.4M
-10.6%
4.9M
R&D
584.0K
-51.5%
1.2M
+6.2%
1.1M
-42.1%
2.0M
-13.0%
2.3M
SG&A
3.4M
-8.8%
3.7M
+82.8%
2.0M
-16.7%
2.5M
-8.6%
2.7M
Operating Income
-3992000
+19.2%
-4942000
-60.5%
-3079000
+30.2%
-4414000
+9.3%
-4868000
EBITDA
-3989000
+19.3%
-4940000
-61.2%
-3064000
+29.9%
-4370000
+9.4%
-4824000
Net Income
-2929000
+34.8%
-4489000
-52.0%
-2954000
+30.5%
-4249000
+8.8%
-4659000
EPS (Basic)
$-0.32
+36.0%
$-0.50
-51.5%
$-0.33
+32.7%
$-0.49
+9.3%
$-0.54
EPS (Diluted)
$-0.32
+36.0%
$-0.50
-51.5%
$-0.33
+32.7%
$-0.49
+9.3%
$-0.54
Shares (Diluted)
9.1M
+1.1%
9.0M
+3.7%
8.7M
-0.6%
8.7M
+1.5%
8.6M
Lisata Therapeutics (LSTA) — Financials